RIBOZYME AND OMICS

ABOUT COMPANY

History

이미지

2017 - 2022

2022
12

Selected as a military service-designated entities(research institute)

10

US FDA IND(phase 1/2a) approval of RZ-001(HCC)

관련기사보기
09

Wins Award for Promising Candidates for Genetic Therapy at International Events

관련기사보기
06

Series C funding complete

관련기사보기
06

Clinical test phase-1/2a of RZ-001 approved by Korean MDFS

관련기사보기
05

INNOBIZ Certification acquired

03

RZ-001 (HCC treatment) Patent granted (JP)

2021
11

Selected as the national new drug development project announced by Ministry of Science and ICT, Ministry of Trade, Industry, and Energy, Ministry of health and Welfare

관련기사보기
10

RZ-003 (Alzheimer’s disease treatment) Patent granted (KR)

08

RZ-001 (HCC treatment) Patent granted (KR)

05

RZ-001 (HCC treatment) Patent granted (US)

03

Bridge funding complete

관련기사보기
2020
12

Selected for Phase 2 of Innovativ drug pipeline discovery by the Ministry of Science and ICT

관련기사보기
11

Successful completion of TIPS program selected by Ministry of SMEs and Startups

01

Participate in Innovative drug pipeline project of Ministry of Science and ICT

2019
11

Head Office relocated from Gwangju to Yongin (Dankook Univ.)

10

Opening Ceremony of Rznomics Inc. (Oct 2, 2019)

09

Series A investment completed

관련기사보기
05

Selected for Innovative drug pipeline discovery project by the Ministry of Science and ICT

2018
05

Korean Venture Capital Association corporate certification and acquired (May 24, 2018)

05

Research Institute founded and certified (May 21, 2018)

2017
12

Seed& Pre-A investment completed (Dec 2017 / Jul 2018)

12

Selected TIPS program by the Ministry of SMEs and Startups (Dec 22, 2017)

11

Registered as R&D Special Zone (Gwangju Innopolis) Research Company (Nov 23, 2017)

10

Technology and patents transfer from Dankook Univ. (Oct 11, 2017)

08

Rznomics Inc. established (Aug 29, 2017)